Researchers Report Long-Term Remissions in First Personalized Cell Therapy Trial

September 2, 2015

(Medical Xpress) – Eight of 14 patients in the first trial of the University of Pennsylvania’s personalized cellular therapy for chronic lymphocytic leukemia (CLL) responded to the therapy, with some complete remissions continuing past four and a half years. These results, published today in Science Translational Medicine, represent the most mature data from clinical trials of an approach known as CTL019, developed by a team from Penn’s Abramson Cancer Center and the Perelman School of Medicine.